Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Official Title

A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol

Summary:

The purpose of this study is to collect and store tumour tissue, blood, and bone marrow samples from patients with soft tissue sarcoma that will be tested in the laboratory. Collecting and storing samples of tumour tissue, blood, and bone marrow from patients to test in the laboratory may help the study of cancer.

Trial Description

Primary Outcome:

  • Collection of human tumour tissue and other biological specimens (blood, serum, and bone marrow) from patients with rhabdomyosarcoma or non-rhabdomyosarcoma soft tissue sarcoma
  • Collection of clinical data on patients who are not being treated on a COG therapeutic study
OBJECTIVES:
I. Collect human tumour tissue and other biological specimens (blood, serum, and bone marrow) from patients with rhabdomyosarcoma or non-rhabdomyosarcoma soft tissue sarcoma diagnosed and/or treated at a Children's Oncology Group (COG) member institution. II. Provide a repository for storage of tissue and other biological specimens collected by COG investigators from these patients. III. Make these specimens available for approved projects by laboratory-based investigators. IV. Collect clinical data on these patients who are not being treated on a COG therapeutic study. V. Define and compare the clinical features of patient subgroups with alveolar rhabdomyosarcoma whose tumours carry the t(2;13), t(1;13) or neither translocation. VI. Investigate the relationship between evidence of submicroscopic disease and response rate (CR/PR), failure-free survival, and survival of patients with alveolar rhabdomyosarcoma, as determined by positive or negative reverse transcriptase-polymerase chain reaction (RT-PCR) assay for the t(2:13) and t(1:13) on peripheral blood and bone marrow specimens obtained at diagnosis. VII. Compare the clinical, cytogenetic, and molecular biologic features of patient subgroups with anaplastic rhabdomyosarcoma and other subtypes of rhabdomyosarcoma. OUTLINE:

Surgical tissue, bone marrow, and blood specimens are collected at diagnosis (initial or relapse) and, if applicable, at the development of a second primary tumour. Specimens are used for research purposes. A certificate of confidentiality protecting the identity of research participants in this project has been issued by the National Cancer Institute. Patients who are not enrolled on a Children's Oncology Group treatment trial are followed every 6 months for at least 10 years or until disease progression or development of a second malignancy.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society